Symptoms and Clinical Signs of Hypogonadism in Testicular Cancer Survivors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-08-31

Study Completion Date

2016-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the prevalence of signs and symptoms of hypogonadism in three groups of testicular cancer survivors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prevalence of Hypogonadism in Male Cancer Patients

NCT00472940

Cancer Hypogonadism

COMPLETED

Short-term Testosterone Replacement in Testicular Cancer Survivors

NCT03339635

Testicular Cancer

COMPLETED PHASE2

MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism

NCT02102646

Prostate Cancer Metabolic Syndrome Hypogonadism +1 more

COMPLETED PHASE4

7 Tesla MRI Neuroimaging in Testicular Cancer Patients With Hypogonadism and on Androgen Replacement Therapy

NCT06191575

Hypogonadism Malignant Testicular Germ Cell Tumor

SUSPENDED

Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men

NCT05773183

Hypogonadism, Male Testosterone Deficiency Prostate Cancer +8 more

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Recent studies have shown that metabolic syndrome is common among testicular cancer. Patients with low levels of testosterone appear to be at higher risk of metabolic syndrome.

A substantial number of testicular cancer survivors might be in a state of "compensated hypogonadism" with testosterone levels low in the normal range due to an increased LH-drive from the pituitary gland.

Whether this specific groups of testicular cancer survivors are at increased risk of cardio-vascular disease and might benefit from testosterone substitution is yet to be clarified.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Syndrome Hypogonadism Cardio-vascular Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Earlier treatment of testicular germ cell cancer
* No sign of relapse \> 1 year since latest treatment
* Testosterone \< 12 nmol/L and luteinizing hormone \> 8 IE/L OR
* Testosterone \> 12 nmol/L and LH \> 8 IE/L OR
* Testosterone and LH within their normal ranges